dipyridamole has been researched along with gemcitabine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bamberger, U; Boven, E; Feller, N; Jansen, WJ; Pinedo, HM; van der Wilt, CL | 1 |
| Belt, JA; Cass, CE; Crawford, CR; Mackey, JR; Mani, RS; Mowles, D; Selner, M; Young, JD | 1 |
| Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S | 1 |
| Ahmad, I; Ahmad, MU; Ali, SM; Chen, P; Chien, PY; Khan, AR; Sheikh, S | 1 |
| Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F | 1 |
| Borch, RF; Peters, GJ; Sigmond, J; Wu, W | 1 |
| Adema, AD; Honeywell, RJ; Losekoot, N; Myhren, F; Peters, GJ; Sandvold, ML; Smid, K; Verheul, HM | 1 |
| Baker, SD; Blum, W; Drenberg, CD; Du, G; Gibson, AA; Gruber, TA; Hu, S; Li, L; Nies, AT; Pabla, N; Pounds, SB; Rhinehart, DP; Schwab, M; Shi, L; Sparreboom, A | 1 |
1 review(s) available for dipyridamole and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for dipyridamole and gemcitabine
| Article | Year |
|---|---|
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Dose-Response Relationship, Drug; Drug Synergism; Equilibrative Nucleoside Transporter 1; Excitatory Amino Acid Antagonists; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Phosphorylation; Proto-Oncogene Proteins c-akt; S Phase; Thioinosine; Thymidylate Synthase; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
8 other study(ies) available for dipyridamole and gemcitabine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; Doxorubicin; Drug Resistance; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Mice; Mice, Nude; Morpholines; Neoplasms; Neoplasms, Experimental; Protein Binding; Transplantation, Heterologous; Triamterene; Tumor Cells, Cultured; Vincristine | 1995 |
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Cell Division; Cell Survival; Deoxycytidine; Dipyridamole; DNA, Complementary; Gemcitabine; HeLa Cells; Humans; K562 Cells; Kinetics; Membrane Proteins; Membrane Transport Proteins; Nucleoside Transport Proteins; Recombinant Proteins; Thioinosine; Transfection; Tumor Cells, Cultured | 1998 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Dipyridamole; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms | 2004 |
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; HT29 Cells; Humans; Leukemia P388; Leukocyte Count; Mice; Mice, SCID; Neutropenia; Nucleoside Transport Proteins; Pancreatic Neoplasms; Thioinosine; Xenograft Model Antitumor Assays | 2006 |
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Nucleoside Transport Proteins; Prodrugs; Structure-Activity Relationship | 2007 |
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
Topics: Antineoplastic Agents; Cell Line; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Nucleoside Transport Proteins; Nucleotidases | 2012 |
OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
Topics: Animals; Antimetabolites, Antineoplastic; Child; CHO Cells; Cohort Studies; Cricetulus; Cytarabine; Deoxycytidine; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; HEK293 Cells; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Organic Cation Transport Proteins; Symporters | 2017 |